WHO South-East Asia Journal of Public Health
  • 74
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 6  |  Issue : 2  |  Page : 60-68

Implementation of G6PD testing and primaquine for P. vivax radical cure: Operational perspectives from Thailand and Cambodia

1 Bureau of Vector Borne Diseases, Ministry of Public Health, Nonthaburi, Thailand
2 National Centre for Parasitology, Entomology and Malaria Control; School of Public Health, National Institute of Public Health, Phnom Penh, Cambodia, Thailand
3 Cambodian Pharmacovigilance Centre, Department of Drugs and Food, Ministry of Health, Phnom Penh, Cambodia
4 National Centre for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia
5 Office of Disease Prevention and Control No. 10, Chiang Mai, Thailand
6 Independent consultant, Bangkok, Thailand

Correspondence Address:
Chansuda Wongsrichanalai
Independent consultant, Bangkok
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2224-3151.213793

Rights and Permissions

Following progressive success in reducing the burden of malaria over the past two decades, countries of the Asia Pacific are now aiming for elimination of malaria by 2030. Plasmodium falciparum and Plasmodium vivax are the two main malaria species that are endemic in the region. P. vivax is generally perceived to be less severe but will be harder to eliminate, owing partly to its dormant liver stage (known as a hypnozoite) that can cause multiple relapses following an initial clinical episode caused by a mosquito-borne infection. Primaquine is the only anti-hypnozoite drug against P. vivax relapse currently available, with tafenoquine in the pipeline. However, both drugs may cause severe haemolysis in individuals with deficiency of the enzyme glucose-6-phosphate dehydrogenase (G6PD), a hereditary defect. The overall incidence of malaria has significantly declined in both Thailand and Cambodia over the last 15 years. However, P. vivax has replaced P. falciparum as the dominant species in large parts of both countries. This paper presents the experience of the national malaria control programmes of the two countries, in their efforts to implement safe primaquine therapy for the radical cure, i.e. relapse prevention, of P. vivax malaria by introducing a rapid, point-of-care test to screen for G6PD deficiency.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded558    
    Comments [Add]    
    Cited by others 7    

Recommend this journal